Zurich’s Züri Can pilot is giving cannabis reformers something stronger than slogans. New interim findings show regulated, nonprofit access reduced several reported health problems while pulling demand away from the illegal market, giving Switzerland fresh evidence for national cannabis reform and putting prohibition panic on weaker ground.
Jersey’s New Cash Crop
Jersey reinvented itself. A forty-five square mile island once known for offshore finance is now exporting pharmaceutical-grade cannabis into Germany’s booming medical market. With strict regulation, heavy investment, and a government eager for diversification, Jersey has become an unlikely European powerhouse. The contradiction between local policing and global commerce tells the real story.
Australia Cracks Down on Medical Cannabis
Australia’s medical cannabis system expanded rapidly through telehealth and high-volume prescribing. Now regulators are tightening oversight. The TGA and AHPRA are increasing scrutiny on prescribing practices, signaling a shift from rapid patient access toward stricter clinical control that could reshape how doctors prescribe and how patients obtain treatment.
Reefer Report Card Vol. 32: Kicking the Can Again
This week’s Reefer Report Card tracks a familiar pattern in cannabis policy: delay dressed as progress. Federal lawmakers punted again on hemp regulation, states flirted with dismantling legal markets, and patients were left waiting. Oversight weakened, accountability faded, and reform stalled. Another week in weed, graded.
WHEN THE UN CAN’T STOP LEGAL WEED
As cannabis reform accelerates worldwide, the UN’s International Narcotics Control Board continues warning that decades old drug treaties still apply. This feature examines the INCB’s actual authority, the limits of treaty enforcement, and why global legalization is advancing despite institutional resistance rooted in prohibition era frameworks.
Reefer Report Card Vol. 31: The Retreat Becomes Routine
Reefer Report Card Vol. 31 examines a week where cannabis reform quietly retreated. Ballot rollbacks gained traction, federal action stalled, and patients remained unprotected. Legal weed stayed popular, but oversight weakened and accountability slipped. Another week where legalization survived while governance failed